skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Docetaxel Formulation CKD-810 (Code C88322)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Docetaxel Formulation CKD-810

Definition: An injectable formulation containing the taxane docetaxel, a semisynthetic analogue of paclitaxel, with antineoplastic activity. Docetaxel binds specifically to the beta-tubulin subunit of the microtubule, stabilizing tubulin and inhibiting microtubule disassembly, which results in cell-cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response.

Label: Docetaxel Formulation CKD-810

NCI Thesaurus Code: C88322 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL413582  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
CKD-810
Docetaxel Formulation CKD-810

External Source Codes: 
PDQ Closed Trial Search ID 661020
PDQ Open Trial Search ID 661020 (check for NCI PDQ open clinical trial info)
NCI META CUI CL413582

Other Properties:
     Name Value (qualifiers indented underneath)
code C88322
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  

URL: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C88322

Mainbox Bottom